Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
1154 results
D2.164 - Pediatric bee venom allergy: family background matters
D2.165 - Safety Profile and Clinical Outcome of Sublingual Immunotherapy (SLIT) with Pru p 3 in Patients with LTP Allergy Undergoing Food Reintroduction
D2.166 - Randomized Controlled Trial of Sublingual Immunotherapy for Egg Allergy
D2.168 - Systemic reactions to subcutaneous immunotherapy in children
D2.170 - The placebo effect leads to significantly lower values regarding allergic symptoms and medication use in birch-pollen allergic patients during the birch pollen season
D2.171 - The individual benefit of subcutaneous immunotherapy with mannan-conjugated birch pollen allergoids is already evident in the first season immediately after treatment
D2.172 - Subcutaneous immunotherapy with a depigmented cat allergoid in patients with cat allergy is safe and results primarily in delayed local reactions
D2.173 - Subcutaneous allergen-specific immunotherapies for inhalation allergens induce higher levels of therapy specific IgG4 antibodies than sublingual therapies: a retrospective data analysis
D2.175 - TAPAS – non-inferiority of clinical effectiveness in children compared to adults: interim results of a long-term NIS
D2.176 - Improved quality of life after PQ Grass in comparison to SLIT products in grass allergic patients
D2.177 - The Efficacy of Sublingual Immunotherapy in Mild versus Moderate Atopic Dermatitis Among Children with House Dust Mite Allergic Rhinitis
D2.178 - Allergen-specific IgE/IgG4 ratio as biomarker of allergen immunotherapy efficacy in house dust mite-sensitized allergic rhinitis
D2.180 - Immunological evaluation of cat allergic individuals living with or without a cat
D2.182 - Low-dose oral food challenge (OFC) in a pediatric day-care hospital: a pre-immunotherapy approach for managing nut-allergies in children
D2.183 - Assessment of Incidence and Onset of Eosinophilic Esophagitis during the clinical development of Peanut (Arachis hypogaea) Allergen Powder-dried non-fat protein for oral immunotherapy
D2.184 - Trends in aeroallergen immunotherapy prescription
D2.185 - Ultrarush honeybee venom immunotherapy in patients with monoclonal mast cell activation syndrome: two case reports
D2.186 - Toxicity Assessment of Repeated Doses of Apis mellifera Venom for Immunotherapy
D2.187 - Can the Conjunctival Allergen Provocation Test Improve Long-Term Adherence to Subcutaneous Allergen-Specific Immunotherapy?
D2.188 - Low allergenicity of food allergen by Galactomannan Conjugation and immunotherapeutic efficacy of peanut-galactomannan conjugate in a mouse model of peanut allergy
Pagination
First page
First
Previous page
Previous
…
Page
42
Page
43
Page
44
Page
45
Current page
46
Page
47
Page
48
Page
49
Page
50
…
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download